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Neuroinflammation is involved in several neurodegenerative disorders and emerging evidence indicates that it
constitutes a critical process that is required for the progression of neurodegeneration. Microglial activation constitutes
a central event in neuroinflammation. Furthermore, microglia can not only be activated with an inflammatory and
neurotoxic phenotype (M1-like phenotype), but they also can acquire a neurosupportive functional phenotype (M2-like
phenotype) characterised by the production of anti-inflammatory mediators and neurotrophic factors. Importantly,
during the past decade, several studies have shown that CD4+ T-cells infiltrate the central nervous system (CNS) in
many neurodegenerative disorders, in which their participation has a critical influence on the outcome of microglial
activation and consequent neurodegeneration. In this review, we focus on the analysis of the interplay of the different
sub-populations of CD4+ T-cells infiltrating the CNS and how they participate in regulating the outcome of
neuroinflammation and neurodegeneration in the context of Parkinson’s disease, Alzheimer’s disease, amyotrophic
lateral sclerosis and multiple sclerosis. In this regard, encephalitogenic inflammatory CD4+ T-cells, such as Th1,
Th17, GM-CSF-producer CD4+ T-cells and γδT-cells, strongly contribute to chronic neuroinflammation, thus perpetuating
neurodegenerative processes. In contrast, encephalitogenic or meningeal Tregs and Th2 cells decrease inflammatory
functions in microglial cells and promote a neurosupportive microenvironment. Moreover, whereas some
neurodegenerative disorders such as multiple sclerosis, Parkinson’s disease and Alzheimer’s disease involve the
participation of inflammatory CD4+ T-cells 'naturally', the physiopathology of other neurodegenerative diseases,
such as amyotrophic lateral sclerosis, is associated with the participation of anti-inflammatory CD4+ T-cells that
delay the neurodegenerative process. Thus, current evidence supports the hypothesis that the involvement of CD4+ T-cells
against CNS antigens constitutes a key component in regulating the progression of the neurodegenerative process.
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The neuroinflammatory process has been associated with
most neurodegenerative diseases including Alzheimer’s
disease (AD), Parkinson’s disease (PD), multiple sclerosis
(MS) and amyotrophic lateral sclerosis (ALS) [1]. Further-
more, emerging evidence indicates that neuroinflamma-
tion constitutes a critical process for the progression of
neurodegeneration involved in neurodegenerative disorders
[2]. Microglial activation plays a central role in neuroin-
flammation, with microglial cells being the main source
of reactive oxygen species (ROS) and nitrogen species,* Correspondence: rodrigo.pacheco@cienciavida.cl
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article, unless otherwise stated.glutamate and TNF-α, all of which are highly neurotoxic
when released in high doses by activated microglia [2-5].
Several studies have shown that microglial activation
may be evoked by the stimulation of toll-like receptors
(TLRs) through the aggregated proteins in the central
nervous system (CNS) of individuals with neurodegen-
erative diseases, as well as in animal models [6-9]. For
instance, a pathological hallmark in the brain of AD
patients includes extracellular deposition of the fibrillar
form of β-amyloid peptide (Aβ) surrounded by dystrophic
neurites, forming senile plaques and intracellular neurofib-
rillary tangles constituted of hyperphosphorylated forms
of the microtubule-binding protein Tau [10]. Similarly to
AD, PD is a proteinopathy that is characterised by the
accumulation and aggregation of misfolded α-synuclein
and ubiquitin in cytoplasmic inclusions called Lewy bodiesd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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found in both sporadic and inherited forms of PD [11].
Similarly, ALS involves the aggregation of superoxide
dismutase 1 (SOD1) in the CNS [12]. Other examples in-
clude associations of aggregated huntingtin in Huntington’s
disease, Prp-amyloid in prion disease and Reelin in aging
brain [1].
Similar to the functional behaviour of peripheral mac-
rophages [2], microglia can not only be activated with
an inflammatory and neurotoxic phenotype (M1-like
phenotype), but they can also acquire a neurosupportive
functional phenotype (M2-like phenotype), characterised
by the production of anti-inflammatory mediators and
neurotrophic factors, including insulin-like growth factor
1 (IGF-1), brain-derived neurotrophic factor (BDNF), glial
cell-derived neurotrophic factor (GDNF), among others
[13-15]. Intercellular interactions between microglia and
other cellular factors play a fundamental role in the out-
come of the functional phenotype acquired by activated
microglia and, therefore, in neurodegeneration. Cellular
factors influencing microglial fate include astrocytes,
neurons, epithelial cells of the blood-brain barrier (BBB)
and T-cells infiltrating the CNS [2]. Indeed, during the
last decade, several studies have shown that CD4+ T-cells
infiltrate the CNS in many neurodegenerative disorders,
and that their participation has a critical influence on the
outcome of microglial activation and consequent neuronal
damage [1,2].
The precise role of CD4+ T-cells infiltrating the CNS
in the outcome of neuroinflammation strongly depends
on the functional phenotype of these cells [2]. Naïve
CD4+ T-cells may be activated by antigen-presenting
cells (APCs) in the presence of diverse mediators and,
depending on the precise composition of the mediators
milieu, they can differentiate different functional phe-
notypes, each of them specialised in orchestrating an
immune responses against a different kind of threat.
For instance, in the presence of IL-12, the differentiation
of CD4+ T-cells toward the T-helper 1 (Th1) phenotype is
favoured, representing a functional phenotype specialised
in the elimination of intracellular pathogens. Furthermore,
this inflammatory phenotype has been associated with
neuroinflammation and neuronal damage [16,17]. The ac-
quisition of the inflammatory Th1 phenotype is controlled
by the master transcription factor Tbet, and the main
effector cytokine produced by these cells is IFN-γ [18].
Another important inflammatory functional phenotype
associated with neuroinflammation and neurodegener-
ation is the Th17 phenotype, which is favoured by the
presence of IL-23 during the activation of naïve CD4+
T-cells. These cells normally play an important role in
gut immunity, as their phenotype is controlled by the
master transcription factor RORγt and their main effector
cytokines are IL-17 and IL-22 [18]. On the other hand,differentiation of the functional phenotype Th2 is con-
trolled by the master transcription factor GATA3, which
is favoured by the action of IL-4, and their main effector
cytokines are IL-13, IL-5 and IL-4. This effector pheno-
type not only plays a fundamental role in the orchestration
of immunity against helminths and in allergy [19], but is
also involved in the attenuation of neuroinflammatory
processes and contributes to the consolidation of spatial
memory under physiological conditions [20-24]. CD4+
T-cells can also acquire an anti-inflammatory functional
phenotype, the T-regulatory phenotype (Treg), which can
suppress the inflammatory function of effector T-cells
[13]. Tregs cells are normally involved in the maintenance
of tolerance toward self-constituents, limiting inflamma-
tory responses against foreign antigens and, importantly,
they are also known to be involved in the attenuation of
neuroinflammation and consequent neurodegeneration
[25-28]. During recent years, these functional phenotypes
of CD4+ T-cells have been shown to participate in the
physiopathology of neurodegenerative disorders. In this
study, we focus on the analysis of the interplay between
the different sub-populations of CD4+ T-cells and how
they participate in regulating the outcome of neuroinflam-
mation and neurodegeneration in the context of PD, AD,
ALS and MS. Furthermore, in the last part of this review,
we analyse the participation of peripheral monocytes/
macrophages infiltrating the CNS, their interaction
with T-cells and their contribution to the regulation of
neuroinflammation.
Role of T-cells infiltrating the CNS parenchyma in multiple
sclerosis
MS represent a neurodegenerative disease in which a
T-cell-mediated response has been known to be in-
volved for more than a decade. MS is a chronic demye-
linating disease generated by an autoimmune response
against constituents of the CNS. This autoimmune
disease affects approximately 2.4 million individuals
worldwide [29]. MS is characterised by the progressive
loss of neurological function caused by the destruction
of the axonal myelin sheath in several areas of the
brain and the spinal cord, which is mediated, mainly,
by self-reactive CD4+ T-cells [30]. The loss of myelin is
manifested in clinical symptoms such as paralysis, muscle
spasms, optic neuritis and neuropathic pain [31]. The
pathological features of MS lesions involve BBB perme-
ability, myelin sheath destruction, axonal damage, glial
scar formation and the presence of inflammatory cells,
mostly lymphocytes, infiltrated into the CNS [32]. The
most used and accepted animal model equivalent of
MS is experimental autoimmune encephalomyelitis
(EAE), which corresponds to an induced autoimmunity
in mice. EAE may be triggered in mice upon injection of
peptides derived from myelin emulsified with adjuvant
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an immunogenic context induces the activation of self-
reactive T-cells that are specific for myelin antigens, me-
diating myelin destruction. This induced autoimmunity
is characterised by focal areas of demyelination along
the brain and spinal cord, with axonal loss that results
in ascending paralysis, affecting first the tail and then
the hind limbs. Self-reactive CD4+ T-cells are activated
by auto-antigen-presenting dendritic cells in peripheral
lymph nodes and, then, the activated self-reactive CD4+
T-cells migrate into the CNS parenchyma. Self-reactive
Th17 cells are the first T-cell population to infiltrate the
CNS, as they express C-C chemokine receptor 6 (CCR6),
which recognises C-C chemokine ligand 20 (CCL20) that
is constitutively expressed on epithelial cells from the
choroid plexus [34]. Th17 cells infiltrating the CNS are re-
stimulated once inside the CNS by resident APCs, which
is followed by microglia activation and production of
IL-1β, TNF-α and IL-6, which contribute to myelin
sheath damage [35]. This initial neuroinflammatory
process results in BBB disruption and the entrance of
leukocytes into the CNS parenchyma. Once T-cells
enter the CNS, they are re-stimulated by resident APCs,
such as astrocytes, microglia or infiltrated APCs such as
dendritic cells and macrophages [36]. Thereby, APCs play
an important role during the course of EAE, as they are
involved in the peripheral activation of T-cells as well as
in the re-stimulation of T-cells inside the CNS. Infiltration
of T-cell into the CNS and their local re-stimulation lead
to the manifestation of clinical symptoms [37]. Although
there are several studies indicating that Th17 and Th1
cells infiltrate the CNS during the course of EAE, recent
studies have shown that none of their signature cytokines
are essential for the development of this disease. In con-
trast to the expression of IL-17 and IFN-γ, the production
of granulocyte macrophage-colony-stimulating factor
(GM-CSF) by autoreactive CD4+ T-cells has proven to
be essential for the development of EAE [38,39]. The
production of this cytokine is stimulated by IL-23 and
by the expression of both transcription factors RORγt
and Tbet, whereas it is inhibited by IL-12, IFN-γ and
IL-27 [38,40]. On the other hand, Tregs progressively
infiltrate the CNS, starting at disease onset. However,
the generation of Tregs and the suppressive activity of
CNS-infiltrated Tregs is impaired by γδT-cells [27].
γδT-cells infiltrate the CNS during EAE, starting at the
onset of disease, reaching the highest cell number at
the peak of disease manifestation before progressively
disappearing from the CNS, thus correlating with the
time course of EAE manifestation [27]. γδT-cells in-
hibit the function of Tregs cells and produce large
amounts of IL-17 in response to IL-23. Once γδT-cells
begin disappearing from the CNS, Tregs continue to
progressively infiltrate the CNS and they can recovertheir suppressive activity, which correlates to the progres-
sive attenuation of EAE manifestation [27]. Another kind
of T-cell that is relevant for EAE is the CD8+ population.
In this regard, some studies involving cell transfer
have suggested the participation of CD8+ T-cell sub-
populations in a pathogenic role of EAE [41]. On the
other hand, there is strong evidence to indicate the
participation of a regulatory sub-population of CD8+
T-cells, which play a beneficial role in EAE [42,43].
Studies show that EAE is more severe in mice that are
deficient in or depleted of CD8+ T-cells, and the disease
severity has been inversely correlated with the frequency
of CD8+ T-cells infiltrating the CNS [41]. In this regard,
distinct sub-populations of CD8+ Tregs have been
described, including CD8+CD28−, CD8+CD122+ and
CD8+LAP+ [44-46]. Importantly, the frequency of CD8+
T-cells is greater than that of CD4+ T-cells in inflamed
plaques from MS patients, and CD8+ T-cells show oligo-
clonal expansion in plaque, cerebrospinal fluid and blood,
suggesting an important role of this cell population in MS.
Taken together, these data indicate the complex role of
several T-cell populations in MS, which finally regulate
microglial activation and, therefore, the outcome of neu-
roinflammation. An overview of the role of the different
T-cell populations participating in neuroinflammation as-
sociated with MS is schematised in Figure 1.
Involvement of T-cell-mediated immune response in
Parkinson’s disease
PD is the second most common neurodegenerative dis-
ease after AD. PD is characterised by the loss of 50 to 70%
of dopaminergic neurons located in the substantia nigra
pars compacta (SNpc). The progressive degeneration of
dopaminergic fibres in the brain results in prominent
motor symptoms, such as bradykinesia, tremors, rigidity
and postural instability. Although studied less in PD than
in MS, the fundamental participation of T-cells has also
been described in PD. An altered frequency of peripheral
CD4+ T-cells has been described in blood samples ob-
tained from PD patients [47,48]. Moreover, CD4+ and
CD8+ T-cells that infiltrated into the brain parenchyma
have been found in post-mortem samples obtained from
PD patients [49,50], as well as in animal models using
mice [50,51] and rats [52]. Recent studies carried out
with T-cell receptor (TCR)-β-chain-deficient mice, SCID
mice and recombination-activating-gen-1 (RAG1) knock-
out (RAG1KO) mice demonstrated that T-cell deficiency
results in a strong attenuation of dopaminergic neurode-
generation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP)-induced PD [50,53]. This reveals that T-cells
are not only relevant, but are also required for neurode-
generation in PD. Additional experiments have shown that
although CD8+ T-cell deficiency is negligible, the partici-
pation of CD4+ T-cells is fundamental for promoting the
Figure 1 T-cell-mediated regulation of neuroinflammation in neurodegenerative disorders. The scheme shows how the participation of
inflammatory and anti-inflammatory subsets of encephalitogenic T-cells might regulate microglial fate and, consequently, the degeneration or
survival of neurons. Whereas Th1, Th17, GM-CSF-producer CD4+ T-cells and γδT-cells favour the acquisition of the neurotoxic M1-like phenotype
by microglia (left side of the illustration), Th2, Tregs and some kinds of CD8+ T-cells can contribute to the promotion of neurosupportive M2-like
phenotype in microglial cells (right side of the illustration). The scheme in (a) shows the 'natural' scenario during the progression of multiple
sclerosis (MS), Parkinson's disease (PD) and Alzheimer's disease (AD), which involve the M1-like microglia and consequent neurodegeneration;
however, upon disease remission or immunosuppressive interventions, it is possible to induce the M2-like phenotype of microglia and neuroprotection.
In the case of PD and AD, only Th1, Th17 and Tregs cells have been associated with the regulation of neuroinflammation. The role of other T-cell
subsets in the regulation of neuroinflammation associated to AD and PD remains unexplored. The scheme in (b) illustrates the participation of T-cells
in the regulation of neuroinflammation associated to amyotrophic lateral sclerosis (ALS). The physiopathological scenario of this disorder 'naturally'
involves the participation of encephalitogenic or meningeal Tregs and Th2 cells, which strongly contribute to the induction of the anti-inflammatory
M2-like phenotype on microglial cells, thus slowing the progression of the neurodegenerative process. BDNF, brain-derived neurotrophic factor; GDNF,
glial cell-derived neurotrophic factor; IGF-1, insulin-like growth factor 1; RNS, reactive nitrogen species; ROS, reactive oxygen species.
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of mice with PD [50]. These studies support the involve-
ment of pathogenic CD4+ T-cell populations, which would
induce the acquisition of an M1-like pro-inflammatory
phenotype by the microglia, which is characterised by the
secretion of inflammatory factors such as TNF-α, IL-1β,glutamate and superoxide [14,54]. Supporting the pivotal
role of CD4+ T-cells potentiating microglial activation and
favouring neurodegeneration in PD, it has recently been
reported that a deficiency of class II major histocom-
patibility complex (MHC) results in attenuation of both
microgliosis and loss of dopaminergic neurons in a
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phenotype of pathogenic CD4+ T-cells involved in PD
have shown that both Th1 and Th17 autoreactive cells
are important for the promotion of neuronal loss [26].
Addressing the molecular mechanisms involved in CD4+
T-cell-mediated loss of dopaminergic neurons in PD, a
study has shown that the participation of Fas-FasL inter-
actions seems to contribute to the neurodegenerative
process [50]. Importantly, we have recently demonstrated
that dopamine receptor D3 (D3R), expressed in CD4+
T-cells, is fundamental in inducing the loss of dopamin-
ergic neurons in the SNpc of a PD mouse model [17]. In
this regard, we and others have reported that D3R-
deficient (D3RKO) mice are resistant to MPTP-induced
PD [17,56]. Interestingly, when wild type (WT) CD4+
T-cells were transferred to D3RKO mice, the animals
acquired the capability to respond to MPTP-induced
neurodegeneration. On the other hand, RAG1KO mice,
which are devoid of T-cells and are resistant to MPTP-
induced PD, acquire the capability to respond to MPTP-
induced neurodegeneration when WT CD4+ T-cells were
transferred, but not when D3RKO CD4+ T-cells were
transferred [17]. Notably, our data indicate that the stimu-
lation of D3R expressed on CD4+ T-cells favours the
acquisition of Th1 inflammatory cells, thus indicating the
crucial importance of this pathogenic phenotype in the
CD4+ T-cells immune response that is involved in PD
[17]. In this regard, we observed that WT, but not
D3RKO, CD4+ T-cells infiltrating the SNpc during
MPTP-induced PD produced high levels of IFN-γ and
TNF-α, which are two cytokines that act synergistically
in microglia, promoting the inflammatory M1-like
phenotype [57]. Thus, these findings point towards the
important role of CNS-derived dopamine in the regulation
of T-cell-mediated immunity during neuroinflammation.
Conversely, other T-cell subsets, such as Tregs and Th2,
could contribute to microglial acquisition of an M2-like
anti-inflammatory phenotype, which release neurotrophic
factors, including IGF-1, promoting neuronal protection
[14,26]. Indeed, it has been demonstrated that Tregs elicit
neuroprotection for dopaminergic neurons of SNpc in
MPTP-induced PD in mice [26,58]. Further analyses have
shown that these Tregs cells act directly on activated
M1-like microglial cells, attenuating migration, phago-
cytosis and the production of neurotoxic factors [58,59].
In vitro experiments have shown that Tregs-mediated
inhibition of M1-like microglia functions occurred through
the suppression of NF-κB activation and required not only
soluble mediators from Tregs, but also cell-cell contacts
with microglial cells [59]. Another group of studies have
also shown evidence of the neuroprotective role of Tregs in
PD. In these studies, copolymer-1 was used as an immuno-
gen, which is a potent inducer of encephalitogenic Tregs
[60]. It has been shown that adoptive transference of CD4+T-cells isolated from mice, immunised with copolymer-1,
attenuates the neurodegeneration of dopaminergic neurons
in SNpc of mice with MPTP-induced PD [61]. On the other
hand, Reynolds et al. found that Th2 cells, which are spe-
cific against CNS antigens involved in PD, do not play a
relevant role, exacerbating or attenuating neurodegenera-
tion in MPTP-induced PD [26]. Other encephalitogenic
T-cell subsets described as playing important inflamma-
tory or anti-inflammatory roles in MS have not yet been
studied in PD. Thus, future efforts are necessary to eluci-
date the participation of anti-inflammatory CD8+ T-cell
subsets, inflammatory γδT-cells and GM-CSF-producer
T-helper cells in the physiopathology of PD. An integra-
tive summary of the role of T-cells in the neurodegenera-
tive process associated with PD is shown in Figure 1.
T-cell-mediated immune response associated with
Alzheimer’s disease
AD is the most common neurodegenerative disorder
worldwide, and it leads to irreversible cognitive impair-
ment and important behavioural alterations. Similar to
PD, T-cells have been detected as infiltrating the brain
parenchyma in close proximity with Aβ deposits in post-
mortem samples of AD patients and in mouse models of
AD [62,63]. Consistent with this observation, Aβ-reactive
T-cells have been found in peripheral blood obtained from
AD patients [64]. Interestingly, Aβ-specific T-cell response
was highly dependent on a particular epitope. IFN-γ has
been shown to play an important role in T-cell-mediated
responses involved in AD. Limited expression of IFN-γ in
the brain favoured T-cell infiltration into the CNS paren-
chyma and the formation of immunosynapses with micro-
glia in a mouse model of AD [62]. Moreover, recent data
indicate that IFN-γ produced by T-cells infiltrating the
brain in AD favour increased microglial activation, Aβ de-
position and impaired cognitive functions [16]. Indeed,
systemic administration of anti-IFN-γ antibody in mice
with AD decreased microglial activation and Aβ depos-
ition, and improve cognitive functions [16]. Interestingly,
vaccination with Aβ peptide has proved efficacious in AD
mouse models [65]. In this regard, transcutaneous im-
munisation with aggregated Aβ plus the adjuvant cholera
toxin results in a high titre of anti-Aβ antibodies and a
significant decrease in cerebral Aβ aggregated in mice
with AD [24]. The fact that most anti-Aβ antibodies
were of IgG1 isotype in this vaccine can be explained by
the induction of a Th2-mediated immune response
using this therapeutic approach; this represents a kind
of immune response that promotes a switch-on micro-
glial M2-like phenotype with consequent neuroprotec-
tion [14,21,25,66,67]. Notably, in the study carried out
by Nikolic et al., they did not detect T-cell infiltration in
the brain parenchyma [24]. Thereby, it is possible that,
when Th2 responses are induced against CNS antigens,
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glial function without infiltrating the brain parenchyma,
as seen in healthy animals [21,66]. The role of Tregs has
also been addressed in AD. The adoptive transference of
Tregs significantly ameliorates impaired cognition and
reduces the Aβ-deposits and microglial activation in a
mouse model of AD [25]. Moreover, higher Tregs function
has been associated with lower cognitive manifestation in
AD patients [68]. Addressing the participation of different
inflammatory phenotypes of CD4+ T-cells infiltrating the
brain during AD, studies indicate an important role for
both Th1 and Th17 cells. In this regard, Browne et al.
examined the role of Aβ-specific CD4+ T-cells on Aβ
accumulation in transgenic mice that overexpress amyl-
oid precursor protein and presenilin-1. The results re-
vealed that Aβ-specific Th1 and Th17 cells infiltrate the
brain in this AD model. To address the relevance of the
different CD4+ T-cell phenotypes in AD, the same authors
generated Aβ-specific CD4+ T-cells by immunisation of
WT mice with Aβ and a TLR agonist, and then polarised
them in vitro towards Th1, Th2 or Th17, which were then
adoptively transferred into mice with AD. Their results
showed that Th1 cells, but not Th2 or Th17 cells, in-
creased microglial activation and Aβ deposition, and these
changes were associated with impaired cognitive function
[16]. Thus, this data indicates a leading role of inflamma-
tory Th1 cells in the immune response associated with
AD. However, there is a group of studies supporting the
relevance of the participation of Th17 cells in the immune
response associated with AD. In this regard, the pheno-
typic analysis of circulating T-cells obtained from AD pa-
tients has shown higher frequencies of the activation
marker CD25 and of CCR6, which is characteristic of
Th17 cells [69], an inflammatory phenotype associated
with neuronal damage in MS and PD [26,30]. Moreover,
significant infiltration of Th17 cells has been detected in
the hippocampus by the immunodetection of the master
transcription factor RORγt and the expression of Th17
cytokines IL-17 and IL-22, which have been associated
with neuron loss and gliosis in cornu ammonis area 1
(CA1) in a rat model of AD [70]. Furthermore, immuno-
histochemical analyses in brain sections of AD animals
showed a high expression of Fas in the hippocampal neu-
rons and a high expression of FasL in Th17 cells that were
in close proximity with neurons. Thus, these findings
suggest that Th17 cells, which were infiltrated into the
hippocampus parenchyma, participate in neuroinflamma-
tion and neurodegeneration of AD by releasing pro-
inflammatory cytokines and by inducing neuron apoptosis
mediated by Fas-FasL contacts [70]. Taken together, the
current evidence indicates that inflammatory Th1 and
Th17 CD4+ T-cells play an important role in the phys-
iopathology of AD, favouring the disease progression
(Figure 1). Nevertheless, other important encephalitogenicT-cell subsets that play important inflammatory or anti-
inflammatory roles in MS have not yet been studied in
AD. Furthermore, studies implementing the genetic
deletion of specific subsets of inflammatory or anti-
inflammatory T-cells would be very helpful in order to
clarify the specific roles and relevance of these different
T-cell subsets in the development and progression of
AD. Therefore, similar to the case for PD, future efforts
are required to evaluate the participation of important
T-cell subsets, such as γδT-cells and GM-CSF-producer
T-helper cells, in the physiopathology of AD.
Involvement of T-cell function in the pathogenesis of
amyotrophic lateral sclerosis
ALS is a neurodegenerative disorder characterised by
selective and progressive degeneration of upper and lower
motor neurons, leading to dramatic muscle paralysis and
death. The initial cause of ALS remains unclear, but nearly
2% of patients have mutations in the Cu/Zn SOD1 gene,
which codes for a ubiquitous protein that acts in removing
dangerous superoxide radicals from inside the cell. It has
recently been proposed that both loss of dismutase activity
and protein aggregation of SOD1 are involved in trigger-
ing neuronal loss in ALS [12]. Transgenic mice that over-
express human mutant SOD1 (mSOD1) develop motor
pathology resembling ALS [71]. Similar to that occurring
in other neurodegenerative diseases such as PD, AD and
MS, neuroinflammation is a prominent feature in the
process of neuronal loss in ALS patients, as well as in
animal models of ALS [1]. Accumulating evidence has
emerged during recent years, indicating that the adaptive
immune system plays an important role in regulating the
progression of ALS [20,23,72]. Interestingly, T-cell infiltra-
tion in spinal cords of ALS mice has been described in
close proximity with dying motor neurons and has been
associated with glial activation [20,23,72]. Nevertheless,
the exact role of the direct interaction of T-cells with
motor neurons in ALS remains unclear. Studies address-
ing the role of T-cells in ALS have shown that T-cell-
deficient mice with ALS, generated by crossing mSOD1
transgenic mice with RAG2KO or with TCR β-chain
knockout (TCRβKO) mice, develop an accelerated pro-
gression to the symptomatic stage of ALS [20,23].
Furthermore, T-cell deficiency in mice models of ALS
is associated with accelerated neuronal loss and decreased
glial activation. Moreover, the reconstitution of mSOD1/
RAG2KO mice with functional T-cells has shown to
recover a prolonged survival of ALS mice, increased
glial activation and delayed neuronal loss [20]. Further
experiments have shown that mSOD1/CD4KO mice dis-
play a phenotype resembling that observed in mSOD1/
RAG2KO mice, thus attributing the neuroprotective role
to CD4+ T-cells, but not to CD8+ T-cells or B-cells [20].
Importantly, ALS mice show microgliosis and astrogliosis
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cantly affect astrogliosis. However, when lacking T-cells
or, specifically, CD4+ T-cells, ALS mice display microglial
cells with attenuated morphological microgliosis, de-
creased activation markers such as CD11b and CD68,
increased levels of pro-inflammatory cytokines such as
IL-6 and TNF-α, decreased levels of trophic factors such
as IGF-1, GDNF and BDNF as well as elevated levels of
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase 2, which is known to enhance microglial release
of ROS [20,23]. All these data indicate that CD4+ T-cells
play a regulatory role on microglial cells during ALS
progression, providing supportive neuroprotection by
favouring the acquisition of the M2-like phenotype by
microglial cells. Recent evidence suggests that both Tregs
as well as Th2 cells actively contribute to the neuroprotec-
tive effect exerted by CD4+ T-cells over microglia. In this
regard, analysis of peripheral blood CD4+ T-cells obtained
from ALS patients has shown decreased levels of Tregs
and a decreased level of protein FoxP3 expression, both of
which result in a lower suppressive activity [73]. Both
parameters were reduced in rapidly progressing ALS
patients, and inversely correlated with the progression
rates [72,74,75]. In addition, both the Th2 cytokine IL-4
and the master transcription factor controlling Th2
phenotype, GATA3, also became reduced in rapidly pro-
gressing patients, inversely correlating with the progres-
sion of motor symptoms [74]. Furthermore, supporting
the participation of Th2 cells during ALS progression,
elevated IL-4 levels were found in spinal cords that were
obtained from mSOD1 mice [23]. Moreover, stimulation
of microglial cells from healthy or ALS mice with IL-4
induces a strong expression of IGF-1 and attenuates the
production of inflammatory cytokine IL-6 [23]. Thus,
current evidence collectively suggests that, by regulating
the acquisition of the functional phenotype of microglia,
Tregs as well as Th2 lymphocytes would play an important
neuroprotective role during ALS progression. See Figure 1
for an integrative overview of the role of T-cells in neuroin-
flammation in ALS.
Contribution of macrophages to the neuroinflammatory
process associated with neurodegenerative diseases
Current evidence indicates that microglial cells play a
key role in sensing protein aggregates in a TLR-dependent
manner in the CNS of patients suffering neurodegener-
ative diseases [6,7]. This initial activation of microglia
produces pro-inflammatory mediators, favouring BBB
permeabilisation and, therefore, the infiltration of periph-
eral leukocytes into the CNS, including T-cells, macro-
phages and others [76]. Macrophages share several
functional features with microglia, including: i) the
expression of TLRs and, therefore, the capability of being
activated by aggregated proteins or pathogen-associatedmolecular patterns [6,7], ii) the expression of class II
MHC and, therefore, the capability to present antigens to
CD4+ T-cells and exert an influence on the functional
phenotype of T-cells [77], and iii) the ability to polarise
their functional phenotype towards an inflammatory M1
phenotype versus an anti-inflammatory M2 phenotype,
which can be influenced by inflammatory T-cells and
Tregs [78]. Thus, when the BBB is already permeabilised,
the possibility arises in which peripheral macrophages
may acquire a relevant role in the outcome of neuroin-
flammation. In fact, there is also evidence suggesting that
a strong inflammatory response in the periphery, such as
systemic lipopolysaccharide (LPS) [79] or viral infections
[80], may result in subsequent infiltration of peripheral
leukocytes into the CNS with consequent neuroinflamma-
tion and neurodegeneration. Therefore, irrespective of
where the inflammatory response is initiated (periphery
versus CNS), macrophages infiltrating the CNS can ac-
quire a relevant role in the outcome of neuroinflammation
associated with neurodegenerative disorders. According to
this notion, there are a number of studies associating
neurodegenerative disorders with alterations in molecular
components, determining the M1/M2 behaviour of per-
ipheral macrophages. In this regard, the anti-inflammatory
surface molecule CD200R is decreased in monocyte-
derived macrophages obtained from the peripheral
blood of PD patients in comparison with those from
healthy donors [81]. Interestingly, the same authors
found that inducible expression of CD200R in monocyte-
derived macrophages correlated inversely with the onset
age of PD and with the capability of these cells to produce
TNF-α [81]. According to the important role of chemoat-
traction of monocytes in inflamed tissues, as well as their
relevance in neurodegenerative disorders, the polymorph-
ism of monocyte chemoattractant protein 1 (or CCL2) has
been associated with the age of PD patients at onset [82].
Similarly, a study found that peripheral blood monocytes
obtained from PD patients displayed a strong up-regulation
of the surface CCR2, which is the receptor for the chemo-
kine CCL2 [83]. Furthermore, according to the relevance of
monocytes/macrophages in PD, a recent study has shown
that the transference of GDNF-transfected macrophages
into mice undergoing 6-hydroxydopamine-induced PD
results in a potent neuroprotective effect [84]. Another
study addressing the analysis of these alterations in
gene-expression profiling of peripheral blood mononuclear
cells obtained from patients undergoing sporadic ALS
found an up-regulation of TLR4-signaling-associated genes
[85], thus suggesting a chronic activation of peripheral
blood monocytes/macrophages in ALS. According to this
idea, Butovsky et al. have found that monocytes obtained
from an ALS mouse model present a polarised M1 pheno-
type and increased CCR2 expression [86]. The same au-
thors have shown that the treatment of ALS mice with
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monocytes, decreased infiltration of M1 macrophages in
the spinal cord and attenuated neurodegeneration [86],
thus indicating a pivotal role of monocytes/macrophages
in the physiopathology of ALS. Similar to the inflamma-
tory phenotype observed in monocytes/macrophages from
PD and ALS patients, studies addressing the characterisa-
tion of peripheral blood monocytes/macrophages of AD
patients have shown that these cells display an increased
M1 phenotype, with increased expression of chemokine
receptors CCR2 and CXCR1 [87,88], and stronger produc-
tion of inflammatory cytokines, including IL-1β, IL-6 and
IL-23 [88,89]. Regarding MS, studies analysing the M1/
M2 profile of monocytes/macrophages obtained from
human blood samples are more difficult to interpret, as
many studies are performed with relapsing-remitting
patients and/or individuals treated with the immuno-
modulatory cytokine IFN-β. However, the relevance of
the M1/M2 profile of monocytes/macrophages has been
addressed in EAE. In this regard, M1 macrophages have
been found in the early stage of acute EAE, whereas the
frequency of M2 macrophages is increased during the
peak of disease manifestation and throughout the recov-
ery stage [90]. Indeed, a reduced M1/M2 ratio in the
profile of monocytes/macrophages in the blood, as well
as in the CNS, promotes an attenuated manifestation of
the disease, whereas an increased M1/M2 ratio favours
relapsing EAE [91]. Furthermore, the administration of
ex vivo-activated M2 monocytes both reduces the severity
of ongoing EAE and favours the expression of immuno-
suppressive molecular profile in CNS lesions [91]. In
addition, experiments carried out in an animal model of
focal demyelinisation have shown that M2 macrophages
promote remyelinisation by inducing oligodendrocyte dif-
ferentiation through a mechanism involving the secretion
of activin-A [92]. Importantly, a study has shown that
GM-CSF production by encephalitogenic CD4+ T-cells is
absolutely necessary for EAE manifestation, and its cel-
lular targets were myeloid cells expressing the GM-CSF
receptor [38]. Furthermore, experiments performed with
bone-marrow chimeras, generating animals with selective
deletion of the GM-CSF receptor in microglia or in
CNS-infiltrating myeloid cells, have demonstrated that
the GM-CSF receptor was required to be expressed in
myeloid cells from a peripheral origin, but not in microglia,
in order to allow EAE manifestation [38]. Taken together,
all of these data indicate that peripheral monocytes/macro-
phages display an inflammatory M1 phenotype in human
individuals suffering neurodegenerative disorders. More-
over, evidence obtained from animal models suggests that
these cells may be relevant in neuroinflammation and in
the progression of neurodegeneration, and their manipula-
tion favouring the M2 phenotype has shown promising
therapeutic potential.Conclusions
Neuroinflammation constitutes a critical process in the
physiopathology of several neurodegenerative disorders,
which is required for the progression of neurodegenera-
tion. Differential activation of microglial cells constitutes
a central point of regulation in neuroinflammation, which
can result in neurotoxic or neuroprotective environments
that are critical for the fate of neurons. Growing evidence
has indicated a fundamental role of CD4+ T-cells in the
regulation of neuroinflammation and consequent neuro-
degeneration in a number of neurodegenerative diseases.
In this regard, encephalitogenic inflammatory CD4+ T-cells
such as Th1, Th17, GM-CSF-producer CD4+ T-cells and
γδT-cells strongly contribute to feed chronic neuroinflam-
mation, thus perpetuating neurodegenerative processes. In
contrast, encephalitogenic or meningeal Tregs and Th2
cells decrease inflammatory functions in microglial cells
and promote a neurosupportive microenvironment. Inter-
estingly, whereas some neurodegenerative disorders such
as MS, PD and AD involve the participation of inflamma-
tory CD4+ T-cells 'naturally', the physiopathology of other
neurodegenerative diseases, such as ALS, is associated
with the participation of anti-inflammatory CD4+ T-cells
that delay the neurodegenerative process. Thus, current
evidence supports the hypothesis that the involvement of
a CD4+ T-cell-mediated response against CNS antigens
constitutes a key component for the progression of the
neurodegenerative process. Furthermore, an increasing
number of studies have shown the relevance of peripheral
monocytes/macrophages in the progression of neuro-
inflammation and their therapeutic potential for neu-
rodegenerative disorders. According to this notion,
immunoregulatory strategies to attenuate inflammatory
CD4+ T-cells or M1 monocytes/macrophages and to
strengthen the function of M2 monocytes/macrophages
or Tregs specific for CNS antigens involved in neurode-
generative disorders should be considered in future
therapies.Abbreviations
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